<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583917</url>
  </required_header>
  <id_info>
    <org_study_id>20NM34</org_study_id>
    <nct_id>NCT04583917</nct_id>
  </id_info>
  <brief_title>Brain Involvement in Dystrophinopathies Part 1</brief_title>
  <official_title>Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5) Part 1: a Multicentre Online Phenotyping and Neurobehavioural Data Collection Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Kempenhaeghe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Hovedstadens Apotek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Necker Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect data from a large cohort of individuals with DMD&#xD;
      and BMD focusing on the neurobehavioural aspects of these conditions and their correlation to&#xD;
      the location of the DMD gene mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intellectual disability and neurobehavioural comorbidities affect at least 50% of the&#xD;
      individuals with Duchenne muscular dystrophy (DMD), which, although a rare genetic disease,&#xD;
      is the most common form of muscular dystrophy in childhood. Several studies have documented&#xD;
      that 25% of the DMD population has intellectual disability with recent studies suggesting&#xD;
      that autism and clinically relevant hyperactivity affects 20% and 25% of DMD boys&#xD;
      respectively. A milder allelic variant, named Becker muscular dystrophy (BMD), has similar&#xD;
      prevalence in the population and is also associated with variable degrees of central nervous&#xD;
      system (CNS) comorbidities, which however have been less well defined.&#xD;
&#xD;
      The investigators will address these deficiencies in a large multicentre study funded by the&#xD;
      European Commission (EU H2020) involving 6 countries (Denmark; The Netherlands; France;&#xD;
      Spain; Italy and UK) with the largest European neuromuscular centres and advocacy groups. The&#xD;
      aim will be to study the neurobehavioural aspects of DMD and BMD as well as their correlation&#xD;
      to the genotype. This study will involve male participants with DMD aged 5-17 years and with&#xD;
      BMD aged 5-50 years. It will comprise of online questionnaires that will be completed either&#xD;
      by a parent of a participant &lt;17 years or an adult participant. The questionnaires take&#xD;
      approximately 70 minutes to complete, however this can be done in multiple sittings.&#xD;
      Currently there is a lack of information to assist the prognosis of CNS comorbidities, as&#xD;
      existing databases and registries typically focus on the motor milestones and physical&#xD;
      disability of these patients. There is therefore, an urgent need to present the course and&#xD;
      outcomes in DMD and BMD patients with a wide range of DMD mutations, to provide information&#xD;
      at the point of diagnosis and onwards for families, clinicians and service providers. It will&#xD;
      also assist in paving the way to greater biological understanding and personalization of&#xD;
      interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CNS Comorbidity Pheotyping</measure>
    <time_frame>90 minutes</time_frame>
    <description>Correlate CNS comorbidity phenotypes with genotype in DMD and BMD patients</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be those followed in the two neuromuscular centres located in London and&#xD;
        Newcastle; via the UK Clinical North Star network, the BIND website and the UK advocacy&#xD;
        groups MDUK, Action Duchenne and Duchenne UK. A similar recruitment process will take place&#xD;
        in the other EU countries, according to local regulations and after having obtained the&#xD;
        relevant local ethical approval.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For DMD patients:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  age 5-17 years&#xD;
&#xD;
          -  genetically-proven diagnosis of DMD&#xD;
&#xD;
          -  genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1:&#xD;
             Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-); or&#xD;
             all isoforms (assigned to DMD group 3)&#xD;
&#xD;
        For BMD patients:&#xD;
&#xD;
          -  age 5-50 years&#xD;
&#xD;
          -  genetically-proven diagnosis of BMD&#xD;
&#xD;
          -  genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1),&#xD;
             of both Dp427 and Dp140 (assigned to BMD Group 2), or of all the isoforms (assigned to&#xD;
             BMD group 3).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of a molecular diagnosis of DMD or BMD&#xD;
&#xD;
          -  Mutation falls outside the regions of interest&#xD;
&#xD;
          -  A severe co-morbidity or planned surgical intervention within 6 months from the study&#xD;
             which could interfere with the well-being of the participant&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>DMD and BMD are sex-linked conditions, which occur predominantly in males.</gender_description>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Muntoni</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Muntoni</last_name>
    <phone>020 7905 2869</phone>
    <email>f.muntoni@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidad Complutense de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr Miranda</last_name>
      <phone>(+34) 91 394 6138</phone>
      <email>ruben.miranda@pdi.ucm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GOSH/UCL</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andria Papageorgiou</last_name>
      <phone>+44 (0)20 3987 2199</phone>
      <email>andriani.papageorgiou.14@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://bindproject.eu/</url>
    <description>BIND: Brain Involvement in Dstrophinopathies study website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Professor Francesco Muntoni</investigator_full_name>
    <investigator_title>Chair of Paediatric Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pseudonymised data will be shared amongst collaborating partners in the project, but details on data sharing are still under discussion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

